Form D · Pharmaceuticals
Synedgen, Inc.
Claremont, CA · CIK 0001471618
Offering snapshot reported Oct 1, 2024 · SEC filing
- Reported sold
- $1.75M Offering amount: $2M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 11, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 1, 2024 | Initial | $1,750,000 | No comparison | 4 | SEC filing |
| Jul 12, 2019 | Initial | $2,500,000 | No comparison | 1 | SEC filing |
| Sep 12, 2017 | Initial | $3,000,000 | No comparison | 3 | SEC filing |
| Nov 8, 2016 | Initial | $3,000,000 | No comparison | 1 | SEC filing |
| Apr 27, 2016 | Initial | $6,000,000 | No comparison | 1 | SEC filing |
| Mar 3, 2015 | Initial | $3,500,000 | No comparison | 1 | SEC filing |
| Aug 13, 2014 | Initial | $607,440 | No comparison | 15 | SEC filing |
| Jul 12, 2013 | Amendment | $3,978,957 | $795,520vs Apr 29, 2013 | 38 | SEC filing |
| Apr 29, 2013 | Amendment | $3,183,437 | $729,166vs May 14, 2012 | 26 | SEC filing |
| May 14, 2012 | Amendment | $2,454,271 | $347,265vs Sep 14, 2011 | 15 | SEC filing |
| May 14, 2012 | Amendment | $2,454,271 | $347,265vs Sep 14, 2011 | 15 | SEC filing |
| May 14, 2012 | Amendment | $2,454,271 | $347,265vs Sep 14, 2011 | 15 | SEC filing |
| May 14, 2012 | Amendment | $2,454,271 | $347,265vs Sep 14, 2011 | 15 | SEC filing |
| Sep 14, 2011 | Amendment | $2,107,006 | $1,112,001vs Oct 20, 2009 | 14 | SEC filing |
| Oct 20, 2009 | Initial | $995,005 | No comparison | 10 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-525514
Source: Form D, filed Oct 1, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Clarke Atwell | Director |
| Shenda Baker | Director, Executive |
| Daniel Bradbury | Director |
| Robert Coughlin | Director |
| Keiki Pua Dancil | Executive |
| Kenton Gregory | Director |
| Kenton Gregory, M.D. | Director |
| Paul C. Grint | Director |
| Paul Grint, M.D. | Director |
| Andrew W. Miller | Director |
| John Morgan | Director |
| Hal Oien | Director |
| Diane Olmstead | Director |
| Kaveri Parker | Executive |
| Larry Shapiro | Director |
| William Weismann | Director, Executive |
| William P. Wiesmann | Director, Executive |
| William P. Wiesmann, M.D. | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1420 N. Claremont Boulevard Suite 105 D
Claremont, CA, 91711
Claremont, CA, 91711